The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety-Reference-Cited by-同舟云学术

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety

Published:2011-09 Issue:9 Volume:106 Page:1594-1602
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Van Assche Gert,Lewis James D,Lichtenstein Gary R,Loftus Edward V,Ouyang Qin,Panes Julian,Siegel Corey A,Sandborn William J,Travis Simon P L,Colombel Jean-Frederic

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2011211.pdf

Reference91 articles.

1. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohns and Colitis Organisation: when to start, when to stop, which drug to choose and how to predict response?;DHaens;Am J Gastroenterol,2011

2. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohns and Colitis Organisation: pregnancy and paediatrics.;Mahadevan;Am J Gastroenterol,2011

3. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.;Hoentjen;World J Gastroenterol,2009

4. Infections in patients with rheumatoid arthritis treated with biologic agents.;Listing;Arthritis Rheum,2005

5. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumoniaassociations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.;Wolfe;Arthritis Rheum,2006

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resuming anti-TNF therapy after development of miliary tuberculosis in Behcet’s disease-related uveitis: a case report;Journal of Ophthalmic Inflammation and Infection;2023-11-28

2. Gastric and Duodenal Fistulas in Crohn’s Disease, a Surgical Challenge: Report of 5 Cases and a Review of the Literature;American Journal of Case Reports;2023-07-19

3. Timing of individualized surgical intervention in Crohn’s disease;World Journal of Gastrointestinal Surgery;2022-12-27

4. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial;The Lancet;2022-05

5. Infliximab-Associated Xanthogranulomatous Pyelonephritis: A Rare Complication;Cureus;2022-01-09